Five strategies for managing medication therapy in polypharmacy patients

Polypharmacy has become a defining feature of contemporary primary care across Australia. As the population ages and chronic conditions become more prevalent, the average number of medicines taken by older Australians has climbed steadily. The Australian Bureau of Statistics reports that more than one in three people aged over 75 takes five or more prescription medicines every day. Pharmacists working in community settings, from Chemist Warehouse counters in Brisbane to independent pharmacies in Perth, encounter these patients every working day.

Managing medication therapy in polypharmacy patients requires more than clinical knowledge; it calls for structured workflows, collaborative habits and systematic scrutiny of every prescription that crosses the dispensary bench. The Therapeutic Goods Administration continues to approve new medicines each year, expanding therapeutic options but also widening the risk of drug-drug and drug-disease interactions. Pharmacists, as the most accessible healthcare professionals in Australia, sit at a critical juncture between prescribers and patients. Their training positions them to recognise potentially inappropriate medicines, identify adherence barriers and intervene before harm occurs.

The workload pressures in Australian community pharmacy are real. Dispensing quotas, complex PBS claiming rules and time constraints can push medication review services to the margins. The gap between what is theoretically possible and what is routinely delivered often leaves patients vulnerable to adverse drug events, falls, confusion and preventable hospital admissions. Closing that gap requires deliberate, evidence-based strategies tailored to the realities of the Australian healthcare system, the Pharmaceutical Benefits Scheme and the diverse communities pharmacists serve.

The following approaches have been refined through practice in metropolitan Sydney, regional Victoria and remote Queensland. They draw on national guidelines, professional standards set by AHPRA and practical wisdom shared by pharmacists across the country. None of them is a silver bullet, but together they can reshape how polypharmacy is handled in everyday practice and improve outcomes for some of the most medicine-burdened patients in the system.

The Australian polypharmacy landscape

Australia's universal health insurance scheme, Medicare, subsidises a wide range of prescription medicines through the Pharmaceutical Benefits Scheme. A patient with heart failure, type 2 diabetes, chronic kidney disease and osteoarthritis may leave a single GP appointment with four new scripts, each carefully indicated yet collectively overwhelming.

General practitioners, specialists, nurse practitioners and dentists all prescribe, often without complete visibility of what other prescribers have ordered. A cardiologist in Melbourne may not see the benzodiazepine prescribed by a psychiatrist in Adelaide. Hospital pharmacists conducting medication reconciliation on admission frequently uncover discrepancies that could have caused harm had they persisted. The fragmentation of care is a structural feature of the system and one of the main drivers of polypharmacy-related complications.

Cultural and linguistic diversity adds another layer. Australia is home to people from more than 300 ancestries, and health literacy varies widely. Aboriginal and Torres Strait Islander peoples experience a higher burden of chronic disease and multimorbidity, often at younger ages than the broader population. Pharmacists practising in places like Redfern, Fitzroy or Cairns must navigate the medicines alongside the social and historical contexts that shape how patients engage with the healthcare system. Strategies for polypharmacy management must therefore be both clinically sound and culturally responsive.

Comprehensive medication reviews

The cornerstone of any polypharmacy intervention is a comprehensive medication review. In Australia, pharmacists deliver this through several funded programs, including MedsCheck, Diabetes MedsCheck and the more detailed Home Medicines Review. An HMR involves the pharmacist visiting the patient at home, gathering every medicine in the house — including discontinued prescriptions, herbal products and supplements — and producing a written report for the GP. The process often reveals expired medicines, duplicated therapies and dosing errors that no brief consultation could surface.

The longer HMR is reserved for higher-risk patients and is particularly valuable for those recently discharged from hospital or with multiple prescribers. Each service rewards clinical expertise, but the real value lies in the rapport built during the visit and the written feedback loop with the GP.

Core benefits of a structured medication review

• Identifies medicines that are no longer indicated or have outlived their original purpose
• Surfaces adverse drug reactions that may have been misattributed to ageing itself
• Creates a documented record that travels with the patient between providers
• Builds trust that encourages patients to disclose complementary and recreational substance use

Once a baseline review has been completed, subsequent reviews become faster and more focused. Pharmacists who integrate reviews into their routine workflow report greater professional satisfaction and stronger relationships with local prescribers, particularly in rural towns where continuity of care is easier to maintain.

Systematic deprescribing

Deprescribing is the supervised process of withdrawing inappropriate medicines under professional supervision. It is not about denying treatment; it is about aligning therapy with current goals of care, life expectancy and quality of life. Australia has endorsed the use of tools such as the STOPP/START criteria and the Beers Criteria through various peak bodies, including the Pharmaceutical Society of Australia. These tools offer structured prompts that help pharmacists and prescribers identify medicines that may cause more harm than benefit.

Clinical prioritisation is the first step. A benzodiazepine prescribed for insomnia twenty years ago is a higher priority for review than a statin started six months ago for primary prevention, particularly if the patient has developed frailty or cognitive impairment. Pharmacists should frame deprescribing conversations around patient goals rather than purely biomedical metrics. A resident of a Sydney aged-care facility may value alertness and balance over a marginal reduction in fracture risk achieved through long-term bisphosphonate therapy.

Deprescribing also requires careful tapering. Abrupt withdrawal of antidepressants, gabapentinoids or opioids can cause distressing symptoms and erode patient trust. Pharmacists are well placed to design tapering schedules, counsel patients on what to expect and coordinate follow-up reviews. In states with real-time prescription monitoring, deprescribing efforts can be tracked through dispensing data, providing objective evidence of progress over time.

Digital tools and real-time monitoring

Australia has invested heavily in digital health infrastructure over the past decade. My Health Record provides a national summary of prescriptions, allergies and discharge summaries, although uptake and clinician engagement remain uneven. Electronic prescribing, rolled out nationally after the COVID-19 pandemic, has reduced transcription errors and made it easier for pharmacists to verify dose changes. Together, these tools create a more complete picture of the patient's medicine exposure than was previously possible.

Real-time prescription monitoring adds another layer of safety. Victoria's SafeScript, Queensland's QScript and Tasmania's DORA system allow prescribers and pharmacists to view a patient's recent dispensing history for controlled medicines at the point of care. New South Wales, Western Australia and the ACT have followed with their own systems, with national interoperability improving each year. For polypharmacy patients, these systems help identify double-doctoring, escalating doses and risky co-prescribing of opioids with benzodiazepines or gabapentinoids.

Digital tools that strengthen polypharmacy reviews

• My Health Record for consolidated prescribing history
• Electronic prescribing for legible, verifiable dose instructions
• Real-time monitoring platforms for controlled medicines
• Pharmacy dispensing software with integrated interaction and renal dose alerts

The challenge is integrating these tools into a busy dispensary workflow without creating alert fatigue. Pharmacists should configure their software to suppress low-value warnings and surface only clinically significant interactions. When a flag is raised, it should trigger a brief, structured conversation with the patient rather than reflex dispensing.

Interprofessional collaboration

Polypharmacy rarely exists in isolation; it is usually a symptom of fragmented care. Effective management depends on pharmacists, GPs, practice nurses, specialists and allied health professionals working from a shared medication list. In Australia, several mechanisms support this collaboration, including Medicare Benefits Schedule items for case conferences and the Team Care Arrangement provisions for patients with chronic disease.

Pharmacists who establish regular case-conference routines with local GPs often find that complex patients are resolved more quickly and with less duplication. A brief hallway conversation in a regional Victorian town, a formal multidisciplinary meeting in a Brisbane super clinic, and a quarterly aged-care medication advisory committee all serve the same function: aligning the team around a coherent therapeutic plan. For patients with multiple prescribers, written communication that confirms the agreed regimen is essential to prevent drift over time.

Digital collaboration is also expanding. Secure messaging platforms, shared care plans embedded in practice software, and pharmacist access to hospital discharge summaries all reduce the gaps that allow polypharmacy to grow unchecked. Pharmacists who proactively share their HMR reports and deprescribing recommendations tend to receive more referrals and more constructive feedback from prescribers, reinforcing the value of the service.

Patient-centred communication

Even the best medication review is wasted if the patient does not understand or agree with the plan. Communication in an Australian context must account for varying levels of health literacy, English proficiency and cultural background. Pharmacists should use plain language, teach-back techniques and visual aids where appropriate. Asking a patient to repeat back how they will take their medicines reveals misunderstandings that open-ended questioning often misses.

Adherence support is a daily practice in community pharmacy. Webster-packs, dose administration aids and blister packing remain valuable for patients with cognitive impairment or complex regimens, but they are not a substitute for genuine counselling. Pharmacists should revisit the regimen at every opportunity, checking for side effects, financial pressures and changing circumstances such as a recent bereavement or a move into residential care.

Aboriginal and Torres Strait Islander peoples may have additional considerations. Some communities have historical reasons to be wary of medicines and the healthcare system. Pharmacists working in Aboriginal Community Controlled Health Organisations, or in mainstream pharmacies that serve large Indigenous populations, often find that time, patience and continuity of staff are more important than any single clinical intervention. Culturally appropriate resources, where available, can make a meaningful difference.

Pharmacists across Australia continue to refine how polypharmacy is managed at the coalface. Insights shared by practising clinicians on Johnathan Laird's blog show that small workflow changes — a standing item in the dispensary for high-risk patients, a monthly HMR slot, a routine call to the local GP — accumulate into safer care over time. Continuing professional development through PSA, SHPA and Pharmacy Guild resources keeps pharmacists current with emerging evidence and policy changes. Each pharmacy will adapt these approaches to its own patient mix, staffing and local relationships. Start with one strategy this month — perhaps a weekly MedsCheck for your highest-risk patients — and build from there. The shared aim is simpler regimens, fewer adverse events and patients who feel heard in the process.